This randomized dose comparison trial examined if higher exercise volume decreased inflammatory biomarkers, associated with postmenopausal breast cancer risk, more than moderate exercise volume. The Breast Cancer and Exercise Trial in Alberta (BETA) was a twocenter, two-armed randomized trial in 400 inactive, healthy, postmenopausal women, aged 50-74 years, with a body mass index of 22-40 kg/m 2 . Participants were randomized to high (300 minutes/week) or moderate (150 minutes/week) volumes of aerobic exercise while maintaining usual diet. Fasting blood concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α), were measured at baseline, six, and 12-months. Intentionto-treat analysis was performed using linear mixed models adjusted for baseline biomarker concentrations. Intention-to-treat analyses of 386 (97%) participants showed no statistically significant group differences for changes in biomarker levels at 6 and 12 months. Additionally, we did not observe any modification of this effect by baseline characteristics of participants. In post hoc analyses based on self-selected exercise level (measured in minutes/week) , CRP decreased by 22.45% for participants who exercised >246 minutes/week (highest quintile) and increased by 0.07% for those who exercised <110 minutes/week (lowest quintile, P-trend=0.04), adjusted for baseline covariates. When this analysis was restricted to include exercise time in the target heart rate zone only, statistically significant trends were observed for both CRP (P<0.01) and IL-6 (P=0.04). Prescribing 300 minutes/week of moderate-to-vigorous aerobic exercise did not improve inflammatory markers compared to 150 minutes/week in postmenopausal women.
INTRODUCTION
Increased levels of pro-inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α) are associated with chronic diseases, such as coronary heart disease, diabetes and, more recently, cancer (1) . Intra-abdominal adiposity increases generally in women post-menopause that can contribute to increased levels of adipocytokines, such as CRP, IL-6, and TNF-α (2, 3) . Indeed, several recent case-control studies have demonstrated an association between breast cancer risk and increased levels of inflammatory cytokines (4, 5) , predominantly in obese, postmenopausal women (6, 7), although these associations have not been consistently observed (8, 9). Of these three pro-inflammatory cytokines, CRP is the most studied as a risk factor for breast cancer in prospective studies. A newly published meta-analysis showed a modest significant increase in risk between the highest and lowest categories of circulating CRP (10), confirming the results of a previous meta-analysis of breast cancer risk with increased levels of both CRP and IL-6 (11).
CRP, IL-6 and TNF-α are characteristic of a low-grade chronic inflammatory state that is increased with physical inactivity or sedentary behaviour (12, 13). Increased physical activity has been shown to reduce chronic, low-grade inflammation and is therefore a promising lifestyle intervention for cancer prevention (14, 15). To date, there have been four randomized controlled interventions and some studies have shown no effect (28, 29). While there is substantial evidence supporting the role of physical activity in decreasing circulating levels of inflammatory biomarkers, the optimal dose of exercise has yet to be determined.
In our previous randomized controlled trial, the Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial, we demonstrated that a one-year aerobic exercise intervention (prescribed 225 minutes per week) decreased circulating CRP, IL-6, and TNF-α levels compared to a usual inactive lifestyle defined as less than 90 minutes per week of physical activity (22) . In an exploratory analysis, we also found that increasing exercise volume was associated with statistically significant linear trends of decreasing levels of these inflammatory markers. The Breast Cancer and Exercise Trial in Alberta (BETA) was designed to investigate the exploratory dose-response findings from the ALPHA Trial further to determine the effect of different volumes (150 versus 300 minutes per week) of aerobic exercise on circulating inflammatory biomarkers. The primary outcome of this trial was changes in adiposity (30), where we observed that higher volumes of exercise were more effective in reducing total fat and other adiposity measures compared to lower volumes. The objective of the present study was to determine the effect of the high compared to the moderate volume exercise intervention on circulating levels of CRP, IL-6, and TNF-α, which were secondary outcomes in BETA.
MATERIALS AND METHODS

Study Population
Detailed methods of BETA have been previously described elsewhere (31). Briefly, the trial was a two-centre, two-armed, year-long randomized controlled exercise intervention trial in alcoholic drinks per week, 6) non-smoker, 7) inactive, 8) able to do unrestricted or progressive physical activity as assessed by physician screening, 9) levels in the normal ranges of cholesterol, fasting blood glucose (<7 mmol/L), thyroid stimulating hormone and alanine aminotransferase, 10) cancer-free and 11) not on a weight loss program or planning to commence one. Inactivity was defined as <90 minutes per week of exercise or if between 90 and 120 minutes per week, having a VO 2max <34.5 ml/kg/min as assessed by a submaximal fitness test.
Exercise Intervention
Women were randomized within each centre to either a moderate or high volume aerobic exercise intervention of 150 minutes per week (n=200) or 300 minutes per week (n=200), respectively, based on Health Canada's physical activity guidelines (32, 33) and those from the
Biomarker Assays
Blood samples were collected from each participant at baseline (60mL), 6 and 12 months (40mL) post-randomization. Blood draws were performed after a minimum 10-hour fast and complete abstinence from exercise and alcohol for 24 hours. High-sensitivity CRP assays were conducted at the Reproductive Endocrine Research Laboratory (University of Southern California, Los Angeles, CA). Hs-CRP (henceforth referred to as CRP) was quantified using solid-phase chemiluminescent immunometric assay on an Immulite 2000 analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA), which had a sensitivity of less than 0.01 mg/dL and an intrabatch coefficient of variation (CV) of 8% and an interbatch CV of 9%. The remaining inflammatory biomarkers of interest were assayed at Eve Technologies (Calgary, AB, Canada) using the Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The cytokine assay consisted of IL-6 and TNF-α, with sensitivities ranging from 0.05-0.48 pg/mL.
The intrabatch CV was 9% for both IL-6 and TNF-α and the interbatch CV was 14% for IL-6 and 11% for TNF-α. Individual analyte values and other assay details are available through Eve Technologies.
Statistical Analysis
For all analyses, the natural logarithm transformation was applied to inflammatory biomarker levels because of the skewed distributions of these measurements, and results are presented after back-transformation. To account for possible acute inflammation at time of blood sampling, participants with extremely high inflammatory biomarker concentrations were excluded from the analyses: the threshold concentration for exclusion was 30 mg/L for CRP, thereby excluding four participants, and 20 pg/mL for IL-6, excluding two participants. There were no excluded participants for the TNF-α analysis since no extreme outliers were identified.
In addition, participants with missing blood samples at any time point were removed from the analysis (n=2).
An intention-to-treat (ITT) analysis using linear mixed models was conducted to determine the intervention effect on inflammatory biomarker levels measured at six and 12 months between moderate and high volume exercise groups. Models for each biomarker were adjusted for baseline values of the biomarker and included the main effects of intervention and time, their interaction term, and a random intercept of subjects accounting for within-subject correlation of each biomarker. The models were used to determine the treatment effect ratio (TER) for the intervention effect, which is the ratio of adjusted geometric means of the biomarker level for the high volume over the moderate volume exercise group. Note that a TER that is greater than 1.0 indicates that the high volume exercise group has the higher adjusted geometric mean of the biomarker level (i.e., stronger inflammatory state) than the moderate volume exercise group. Potential confounding was assessed by examining the change in the β-coefficient with and without the potential confounder in the model. We confirmed that baseline differences between the two randomization groups in dietary intake, cholesterol levels, arthritis and use of non-steroidal anti-inflammatory drugs did not confound our inference on intervention effects.
Potential moderation (effect modification) of the intervention main effect was hypothesized a priori, as previously done in other analyses from the ALPHA Trial (22, 36). To assess moderation, the statistical significance of the interaction term (P heterogeneity ) between intervention group assignment and each proposed moderator at baseline was evaluated. In addition to the ITT analysis, an analysis by self-selected exercise volume was also evaluated. Participants were divided based on quintiles of mean minutes of exercise completed per week, as well as by the mean minutes per week spent in their target heart rate zone. TERs were calculated within each exercise volume quintile. A linear trend test was used to test for a linear association between exercise volume quintile and change in inflammatory biomarker from baseline to 12 months, based on a linear model predicting change at 12 months from baseline, where volume quintiles were treated as a continuous variable. All analyses were conducted using Figure S1 ). Overall, 14 women did not complete the study, leaving a study population of 195 women in the high volume exercise group and 191 women in the moderate group (97% retention rate). Blood samples at 12 months post-randomization were obtained for each of these women and were included in the statistical analyses. Baseline characteristics were very similar between randomization groups (Table 1 ). There were no statistically significant differences between groups, with the exception of baseline CRP values, which were slightly higher in the moderate volume exercise group (P=0.04).
In the ITT analysis, there were no significant differences between exercise intervention groups for all three biomarkers ( Table 2 ). In terms of the intervention effect, the TERs for all three biomarkers were all greater than or equal to the null value of 1.0, although not statistically significantly so, indicating that changes favored the moderate volume exercise intervention compared to the high volume exercise intervention. No confounders were identified in our assessment for potential confounding based on the a priori criteria described in the methods section.
When assessing moderation, we did not identify any significant moderators, although we did observe trends with CRP and TNF-α when stratifying by physical fitness, age, BMI and body fat percentage (Table 3 ). In general, we observed that the TERs were higher and at times approaching statistical significance, in participants with higher BMI (>30 kg/m 2 ), body fat percentage (>40.3%) and age at baseline (>60 years), as well as lower physical fitness (VO 2 max<27.2 mL/kg/min) at baseline.
Lastly, we performed an analysis stratified by self-selected exercise volume of all study participants who completed the trial, based on quintiles of mean minutes per week of exercise (Table 4) , as well as mean minutes per week of exercise in their target heart rate zones (Table 5) . When considering the amount of time spent in the target heart rate zone, an even stronger trend was found across all quintiles of exercise time and reduction of CRP levels (P trend <0.01). A linear trend was also observed for the reduction in IL-6 levels with increased exercise time spent in the target heart rate zone (P trend =0.04), despite non-statistically significant differences between the change in the four higher quintiles compared to the lowest, referent quintile. No trends or differences between exercise volume quintiles were observed for TNF-α.
DISCUSSION
In this year-long randomized dose comparison trial of 300 versus 150 minutes per week of aerobic exercise in postmenopausal women, we found no evidence of differential effects on inflammatory biomarkers related to breast cancer risk. Effect modification was not found by physical fitness (measured by VO 2 max), age, past year recreational activity, BMI, body fat percentage or baseline levels of CRP, IL-6 and TNF-α. In secondary analyses based on selfselected exercise volume levels, we found that there was a linear trend associated with increased reductions in CRP levels with increased exercise time in the target heart rate zone.
While baseline characteristics between randomization groups were similar, we observed a significant difference in baseline CRP values. Specifically, baseline CRP levels in both groups Interestingly, although we did not observe significant differences between groups in our ITT analysis, the point estimates of the TERs suggested that the moderate volume exercise program may be more effective in reducing levels of CRP, IL-6 and TNF-α. However, there were some differences in baseline levels of inflammatory biomarkers between randomization groups and, in particular the high volume group had significantly lower CRP values at baseline.
While it is possible that a lower volume of exercise could be more effective in reducing inflammatory biomarkers, it is also possible a minimum threshold of CRP levels may exist in postmenopausal women, thereby making it more difficult for participants in the high volume group with lower CRP levels at baseline to reduce CRP levels further.
There has been one previous study, known as the Dose-Response to Exercise in postmenopausal Women (DREW) that examined the effect of physical activity dose-response on inflammatory biomarkers in postmenopausal women for cardiopulmonary health. The DREW Trial found no direct effect of any amount of exercise on levels of CRP, IL-6 of TNF-α (40-42).
However, three previous RCTs of exercise interventions in postmenopausal women found that an exercise or exercise and diet intervention significantly reduced levels of CRP compared to nonexercise controls: this effect was predominantly mediated by changes in adiposity (20-22).
Baseline BMI was a moderator in one study as the effectiveness of the exercise intervention was only evident in obese women (BMI>30 kg/m studied as a source of pro-inflammatory cytokines, thus larger decreases in adiposity can lead to decreased levels of circulating cytokines (43, 44).
In our analysis of potential moderation in the present study, we did not find any statistically significant interactions between the intervention effects and the potential moderators examined. There were, however, trends in the data, as we found that the moderate volume exercise group had greater decreases in CRP and IL-6 when the analysis was restricted to those participants who were, at baseline, below the median physical fitness (VO 2max <27. indicating that women who are older, less fit or more obese have higher levels of chronic inflammation and may benefit more from a moderate volume exercise intervention compared to a high volume. In terms of treatment effects, we speculate that the high volume exercise prescription in older, less physically fit, or more obese women could potentially be causing more inflammation, thus making the moderate volume exercise prescription more effective in reducing levels of CRP and IL-6. Analyses by subgroups of potential moderators were not performed for inflammatory markers in the DREW study (40-42), and thus there are no similar studies with which to compare our results.
In considering the overall effect of exercise time, there was indeed a significant trend of decreasing CRP levels with increasing exercise time. In these analyses stratified by self-selected exercise level, we observed a mild bi-modal effect, with the strongest percent decreases in CRP rate zone is potentially more important than the total exercise time in inducing changes in inflammatory biomarkers, since we observed an even stronger association between exercise time and CRP levels and also observed a significant trend effect with IL-6 in these analyses than in the analyses of total exercise time. Hence, exercise intensity, in addition to dose, is relevant when determining the impact of physical activity on inflammatory biomarkers in relation to breast cancer prevention. Limited research has examined the role of exercise intensity on changes in inflammatory biomarkers, although some observational studies have found that higher exercise intensity is associated with reduced levels of CRP (45-48), IL-6 (45) and TNF-α (45).
One RCT in young adults found that higher intensity exercise reduced circulating TNF-α levels more effectively than lower doses (49), however, this finding has not been consistently demonstrated in RCTs for TNF-α or other inflammatory biomarkers (50, 51). Results from our study suggest that longer periods of vigorous exercise could be more beneficial in reducing chronic inflammation although more research in this area is necessary to corroborate this finding.
In this study of inflammatory biomarkers, the strongest associations of exercise were with CRP which is known to be a very sensitive and objective systemic marker for inflammation and the acute phase response to tissue damage, infection and malignant neoplasia, where concentrations of circulating CRP can increase up to 10,000 fold in response to stimulus (52). It is also one of the most studied biomarkers, particularly with respect to cardiovascular disease 
inflammatory effect (56). While this increase in IL-6 has been observed predominantly after an acute bout of higher intensity exercise, the anti-inflammatory effect of IL-6 could be a possible mechanism by which physical activity reduces chronic inflammation. This situation could possibly explain why anti-inflammatory effects were strongest in those with the highest levels of high intensity exercise in our analysis of time in target heart rate zone.
To our knowledge, BETA is the first randomized controlled trial to examine the impact of aerobic exercise volume on biomarkers for breast cancer prevention. Overall, we did not observe significant differences between the high and moderate volume exercise groups. In secondary analyses based on self-selected exercise volume, we found that there was a stronger reduction of CRP and IL-6 with increased exercise time. Further research based on exercise intensity and exercise volume is necessary to support our conclusions.
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Ridker The TER was calculated based on a linear mixed model for each biomarker, adjusted for time and baseline value of the biomarker. The TER represents the adjusted ratio of geometric means for the high exercise group over the moderate exercise group. A TER of less than 1.0 indicates lower inflammatory marker levels in the high exercise group relative to the moderate exercise group at 6 and 12 months; a TER greater than 1.0 indicates higher inflammatory marker levels in the high exercise group; and a ratio of 1.0 indicates no difference between exercise groups. The TER represents the adjusted ratio of geometric means for the high exercise group over the moderate exercise group. A TER of less than 1.0 indicates lower inflammatory marker levels in the high exercise group relative to the moderate exercise group at 6 and 12 months; a TER greater than 1.0 indicates higher inflammatory marker levels in the high exercise group; and a ratio of 1.0 indicates no difference between exercise groups. e P-value refers to the statistical significance of the interaction term between the high volume exercise group and the potential moderator. All moderators were treated as continuous variables for this calculation.
Abbreviations: CI, confidence interval; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor α; BMI, body mass index. Percentage change in adherence group mean of each inflammatory biomarker at 12 months from baseline, adjusted for the baseline inflammatory marker level, age, VO 2 max and body mass index.
e P-value tests difference in changes in inflammatory biomarker levels between the lowest quintile adherence group and the specified adherence group, adjusted for the baseline value of the inflammatory biomarker, age, VO 2 max and body mass index. A unified model, where the adherence group was treated as a categorical variable was used to calculate the p-values, which correspond to betacoefficients for the other quintile groups, using the lowest quintile group as the referent group. Mean time in zone was calculated as the mean minutes of exercise time in the target heart rate zone over weeks 1-52 of the study. Blood samples from n=386 participants were obtained. Participants with extremely high inflammatory biomarker values were excluded from the analysis. The threshold for removal and number of participants removed for each biomarker were: CRP: 30 mg/L, 4 participants, IL-6: 20 pg/mL, 2 participants, TNF-α: no extreme values, 0 participants. Participants missing a blood sample at any time point were also removed.
